Yoseph Bornstein - 02 Nov 2023 Form 4 Insider Report for Microbot Medical Inc. (MBOT)

Reporting relationship: Director
Issuer ticker: MBOT
Reported as of: 02 Nov 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Nov 2023, 16:15:24 UTC
Prior SEC filing: 23 Sep 2022
Next SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Yoseph Bornstein

Key filing fact

Yoseph Bornstein filed Form 4 for Microbot Medical Inc. (MBOT) on 06 Nov 2023.

Key facts

This page summarizes Yoseph Bornstein's Form 4 filing for Microbot Medical Inc. (MBOT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Nov 2023, 16:15.

Change

Previous filing in this sequence was filed on 23 Sep 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MBOT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +74,218
Change %
Price: $0.000000
Shares after: 74,218
Date: 02 Nov 2023
Ownership: Direct
Underlying class: Common Stock, par value $0.01 per share
Underlying amount: 74,218
Exercise price: $1.28
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan, as amended: (a) on May 2, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock.